DexCom (NASDAQ:DXCM) PT Lowered to $87.00 at Leerink Partners

DexCom (NASDAQ:DXCM) had its price target reduced by analysts at Leerink Partners from $90.00 to $87.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical device company’s stock. Leerink Partners’ target price points to a potential upside of 19.10% from the stock’s previous close.

Several other equities analysts have also issued reports on DXCM. Barclays decreased their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Morgan Stanley lowered their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. UBS Group dropped their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. BTIG Research reduced their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $109.88.

DexCom Stock Down 2.4 %

Shares of NASDAQ:DXCM opened at $73.05 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock has a market cap of $29.05 billion, a price-to-earnings ratio of 47.13, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a 50 day moving average of $70.13 and a 200-day moving average of $98.71. DexCom has a one year low of $62.34 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The firm had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. On average, sell-side analysts forecast that DexCom will post 1.69 earnings per share for the current year.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DXCM. Vanguard Group Inc. lifted its stake in DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of DexCom by 1.4% during the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after buying an additional 64,683 shares in the last quarter. Legal & General Group Plc increased its holdings in DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Finally, 1832 Asset Management L.P. boosted its position in shares of DexCom by 1.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after purchasing an additional 20,400 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.